-
The registration volume of Chinese herbal medicine-related companies has fallen, and the market concentration will further increase
Time of Update: 2021-12-06
Specifically, it can be seen from the development status of Chinese herbal medicine-related companies in the past ten years that the overall number of company registrations is increasing.
-
The seventh batch of nationally collected varieties has met the conditions (list attached)
Time of Update: 2021-12-06
According to the WeChat public account "Yao Chunqiu", some products of antibacterial drugs currently meet the conditions for entering the seventh batch of national procurement (only based on the competition pattern of enterprises ≥ 3, and other factors such as patents have not been considered for the time being) .
-
CDE releases new regulations for the development of anti-tumor drugs!
Time of Update: 2021-12-06
The highest goal of new drug research and development is richer in connotation In July of this year, the "Guiding Principles" first appeared in the form of a draft for comments and aroused the attention of the industry.
-
It burned nearly 30 billion in 4 years and has yet to make a profit. Why did BeiGene get IPO approval?
Time of Update: 2021-12-06
The listing also created two new records-BeiGene became the world's first biotech company to be listed on the Nasdaq, China Hong Kong Stock Exchange and the Shanghai Stock Exchange; the proposed fundraising scale for this IPO has reached 20 billion, or will break the record of the highest amount of funds raised by biotech companies since the launch of the Science and Technology Innovation Board .
-
In the first week of the Beijing Stock Exchange, 10 listed pharmaceutical and biological companies made their debut!
Time of Update: 2021-12-06
In addition to these two listed pharmaceutical companies, the research and development expenses of Senxuan Pharmaceutical and Yongshun Biological in the first half of the year were also more than 10 million yuan, and the proportion of operating income remained above 5% on average .
-
Over 1.5 billion anti-infection varieties!
Time of Update: 2021-12-06
A few days ago, the official website of the State Food and Drug Administration showed that the Moxifloxacin Hydrochloride and Sodium Chloride Injection from Sichuan Meidakang Huakang Pharmaceutical was approved as a supplementary application .
-
Huiyu Pharmaceutical wins 1.5 billion injections
Time of Update: 2021-12-06
On November 5, the official website of NMPA showed that Huiyu Pharmaceutical's Palonosetron Hydrochloride Injection, which was produced in the generic category 4, was approved for marketing, which was deemed to have passed the consistency evaluation .
The sales situation of Palonosetron injections in China's public medical institutions (unit: 10,000 yuan) Source: Mynet.
-
my country's multiple anti-coronavirus drugs enter clinical trials
Time of Update: 2021-12-06
Li Jia, director of the Shanghai Institute of Materia Medica, Chinese Academy of Sciences: Both new drugs have completed preclinical studies and entered clinical trials.
Li Jia, director of the Shanghai Institute of Materia Medica, Chinese Academy of Sciences: Both new drugs have completed preclinical studies and entered clinical trials.
-
The first Alzheimer's disease vaccine entered clinical trials in 20 years
Time of Update: 2021-12-06
ArticleMedicine GuanlanUS time on November 16, news, Brigham and Women's Hospital (Brigham and Women's Hospital) announced that it will start a phase 1 clinical trial to evaluate a new nasal vaccine in preventing and slowing the progression of Alzheimer's disease (AD) The safety and effectiveness .
-
Norepinephrine bitartrate injection, a subsidiary of Tianyao Pharmaceutical, passed the consistency evaluation
Time of Update: 2021-12-06
On November 18, Tianyao Pharmaceutical issued an announcement stating that its subsidiary Jinyao Pharmaceutical had received the "Drug Supplementary Application Approval Notice" for norepinephrine bitartrate injection approved and issued by the National Medical Products Administration, and approved it The drug passed the quality and efficacy consistency evaluation of generic drugs .
-
The TOP20 market for tens of billions of cold Chinese patent medicines is released! 2 billion large varieties lead 6 exclusive lists
Time of Update: 2021-12-06
As the best-selling category in the retail market, the terminal sales of cold Chinese patent medicines in physical pharmacies in Chinese cities have exceeded 10 billion yuan, and China Resources Sanjiu Pharmaceutical has continued to rank as the top seller .
-
Yichang Renfu Pharmaceutical declares a new indication for the sedative "remazolam"
Time of Update: 2021-12-06
ArticleMedicine GuanlanOn November 17, the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China announced that Yichang Renfu Pharmaceutical, a holding subsidiary of Renfu Medicine, has submitted a new indication for the listing of "remazolam besylate for injection".
-
There is a large demand for Chinese medicine talents, and the establishment of a training system needs to be promoted at the same time in many aspects
Time of Update: 2021-12-06
For this reason, in recent years, China has begun to issue a series of favorable policies to consolidate the foundation of Chinese medicine talents and improve the overall level of Chinese medicine education .
-
This week, a number of domestic blockbuster drugs were approved for listing
Time of Update: 2021-12-06
On November 19, the drug approval information on the NMPA website showed that the 4 types of generic sildenafil citrate tablets of Nanjing Hailing Pharmaceutical Group of Yangtze River Pharmaceutical Group were approved for marketing and reviewed .
-
Announcement of the latest collection documents for 76 major varieties of Chinese patent medicines
Time of Update: 2021-12-06
Double envelope competitionIn the quotation stage, pharmaceutical companies first need to meet the benchmark price, and at the same time, they will be selected based on the comprehensive scores of the representative products of the quotation and the recognition of medical institutions, corporate rankings, supply capabilities, innovation capabilities, recruitment credit rating, drug quality and safety, etc.
-
Treat diabetes! Osaikang Pharmaceutical's Enpagliflozin Tablets was approved for listing!
Time of Update: 2021-12-06
In December 2016, Enpagliflozin was approved by the FDA as a new indication for reducing the cardiovascular risk of patients with type 2 diabetes .
-
Children's medicine welcomes the policy dividend again, and the market space is becoming wider and wider
Time of Update: 2021-12-06
Under the policy-guided research and development of children's drugs and the liberalization of the "three-child policy", the industry predicts that the market size of children's drugs will continue to maintain an average annual growth rate of more than double digits for a long time to come .
-
The continuous acceleration of domestic pharmaceutical equipment going overseas will drive the continued high growth of the company’s performance
Time of Update: 2021-12-06
It is worth mentioning that on July 21st, Chutian Technology also stated in an institutional survey that in the next 3-5 years, the company plans to maintain an annual increase of 10%-20% in its export business.
-
In the tens of billions of cold Chinese patent medicine market, market competition is intensifying
Time of Update: 2021-12-06
In addition to China Resources Sanjiu, Shijiazhuang Yiling Pharmaceutical's share in the cold medicine market has also increased significantly in recent years .
-
Statistical Guidelines for Clinical Research of Rare Disease Drugs (Draft for Solicitation of Comments) released
Time of Update: 2021-12-06
On November 18th, CDE drafted the "Guiding Principles for Clinical Research of Rare Disease Drugs (Draft for Comment)", which is now open for comment .
“Guidelines for Statistics of Clinical Research on Rare Disease Drugs (Draft for Comment)” feedback form for soliciting opinions
